A pesquisa desenvolvida no Laboratório de Pesquisa em Suínos, da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo, Campus de Pirassununga, estudou os efeitos de diferentes doses de LH suíno exógeno na indução e sincronização da puberdade em marrãs. Sessenta e sete fêmeas Camborough - 22 Agroceres PIC® com 140 dias de idade e 86 kg de peso vivo foram submetidas aos seguintes tratamentos: controle T1 (n = 21) - emprego de 600 UI de eCG (gonadotrofina coriônica eqüina) (Novormon&reg) e 72 horas depois 5,0 mg de LH (hormônio luteinizante) (Lutropin® - V); tratamento 2 T2(n = 23) - 600 UI de eCG (Novormon®) e, 72 horas depois, 2,5 mg de LH (Lutropin® - V) e tratamento 3 T3(n=23) - 600 UI de eCG (Novormon®) e, 72 horas depois, 1,25 mg de LH (Lutropin® - V). O estímulo com macho adulto era feito duas vezes ao dia, sendo a ovulação detectada pela ultra-sonografia transcutânea e a taxa de ovulação, pela contagem do número de corpos lúteos (CL) ao abate. O percentual de estro foi semelhante entre T1 (42,85%), T2 (60,87%) e T3 (52,18%), não havendo diferença estatística significativa (P=0,418). O percentual de fêmeas com degenerações císticas foi de 33,33% (T1); 39,13%(T2) e 39,13%(T3), não havendo diferença significativa entre os tratamentos (P=0,9057). O melhor intervalo tratamento - ovulação (LH - OV) ocorreu no grupo de fêmeas submetidas ao T2 (38,26 ± 2,84) demonstrado pela menor dispersão dos desvios comparando com T1 (37,17 ± 4,07) e T3 (36,25± 5,69), sendo o valor do desvio padrão diferente estatisticamente do de T3, porém igual ao valor de T1 sendo ainda o valor de T1 igual ao de T3(P<0,05). O intervalo entre a aplicação de eCG e estro do T1(85,33 ± 12,64 horas), T2 (84,40 ±17,50 horas) e T3 (89,14 ± 14,66 horas) foram semelhantes não havendo diferença estatística significativa (P= 0,6954). A duração do estro foi semelhante entre os três tratamentos (P = 0,2653), sendo de 41,44 ± 16,30 horas (T1); 48,57 ± 16,29 horas (T2); 39,33 ± 11,42 horas (T3). O número de Corpos Lúteos em T1 foi de 9,61 ± 5,43 (1-25); em T2 de 9,86 ±3,32 (1-16); em T3 de 8,13 ± 5,52 (0-20), não constatando diferença significativa (P=0,4259). Os menores desvios observados no tratamento T2 sugerem que a combinação de 600 UI de eCG seguida por 2,5 mg de LH após 72 horas, foi a mais efetiva na indução e sincronização do estro e ovulação em fêmeas suínas pré-púberes, considerando a metodologia experimental empregada. Na segunda parte do experimento, foram realizadas inseminações artificiais em tempo fixo em dois esquemas (E) diferentes: O (E1) recebeu uma única dose 36 h após a aplicação de LH e, o (E2) recebeu a primeira dose 24 h e a segunda dose 36 h após a aplicação de LH. As marrãs foram abatidas com 5 dias de gestação e os embriões foram colhidos. Não verificou-se diferença estatística entre os valores obtidos na taxa de recuperação (36,81±5,21 para E1 e 36,91±4,62 para E2), taxa de viabilidade embrionária (TVE) (59,28±6,91 para E1 e 62,25±6,26 para E2), taxa de fecundação (TF) (72,60±7,06 para E1 e 79,33±6,26 para E2) e número de estruturas totais (3,41±0,57 para E1 e 3,77±0,50 para E2) entre E1 e E2. Houve interação significativa entre tratamento e número de doses de sêmen para as variáveis TVE (T1=60,51± 8,18, T2=68,64±7,94 e T3=53,14±7,8) e TF (73,50±8,36 para T1, 89,93±8,11 para T2 e 64,46±8,05 para T3) (P=0,0036). Novos estudos envolvendo aplicação dos hormônios e n° de doses de sêmen, necessitam serem repetidos. / The research carried out at the Swine Research Laboratory, of FMVZ - USP, Campus of Pirassununga, studied the effects of the use of different hormonal doses on the induction and synchronization of puberty in gilts. Sixty-seven Camborough 22 Agroceres PIC® females with 140 days of age and 86kg of body weight were submitted to the following treatments: control T1 (n=21) - use of 600 IU of eCG (equine chorionic gonadotrophin) (Novormon®) and 72 hours later 5,0 mg of LH (Luteinizing hormone) (Lutropin® - V); treatment 2 T2 (n = 23) - 600 UI of eCG (Novormon®) and 72 hours later 2,5mg of LH (Lutropin® - V) and treatment 3 T3 (n = 23) - 600 UI of eCG (Novormon®) and 72 hours later 1,25mg of LH (Lutropin® - V). Adult boar stimulation was implemented twice a day, and ovulation was detected through transcutaneous ultrasonography and ovulation rate by corpora lutea (CL) counting at slaughter. The percentage of estrus was similar in T1 (42,85%), T2 (60,87%) and T3 (52,18%), and there was no significant statistic difference (P=0,418). The percentage of females with cystic degeneration was 33,33% (T1); 39,13%(T2) and 39,13%(T3), being no significant difference between the treatments (P=0,9057). The best interval between treatment and estrus (LH - OV) occurred in the group of females submitted to T2 (38,26 ± 2,84) demonstrated by lesser dispersion of the deviations comparing to T1 (37,17 ± 4,07) and T3 (36,25± 5,69); standard deviation was statistically different from T3, but similar to T1, and T1 was also similar to T3 (P<0,05). The interval between the administration of eCG and estrus in T1 (85,33 ± 12,64 hours), T2 (84,40 ±17,50 hours) and T3 (89,14 ± 14,66 hours) were similar, and there was no significant statistic difference (P= 0,6954). The duration of estrous was similar among the three treatments (P = 0,2653), being 41,44 ± 16,30 hours (T1); 48,57 ± 16,29 hours (T2); 39,33 ± 11,42 hours (T3). The number Corpus Luteum in T1 was 9,61 ± 5,43 (1-25); in T2 was 9,86 ±3,32 (1-16); in T3 was 8,13 ± 5,52 (0-20), and there was no significant difference (P=0,4259). The minor deviations observed in treatment T2 suggest that the association of 600 UI of eCG followed by 2,5 mg of LH after 72 hours, was more effective in the induction and synchronization of estrous and ovulation in pre-puberty female swine, considering the experimental methodology used. In the second part of the experiment, artificial insemination was performed at determined timing following two different programs (E). E1 received a single dose 36 hours after administration of LH and E2 received the first dose after 24 hours and the second dose 36 hours after the administration of LH. The gilts were slaughtered with 5 days of pregnancy and the embryos were collected. No statistic difference was observed among the values obtained for recovery rate (36,81±5,21 for E1 and 36,91±4,62 for E2), embryonary viability rate (TVE) (59,28±6,91 for E1 and 62,25±6,26 for E2), fecundation rate (TF) (72,60±7,06 for E1 and 79,33±6,26 for E2) and number of total structures (3,41±0,57 for E1 and 3,77±0,50 for E2) among E1 and E2. There was significant interaction between treatment and the number of doses of semen for the values TVE (T1=60,51± 8,18, T2=68,64±7,94 and T3=53,14±7,8) and TF (73,50±8,36 for T1, 89,93±8,11 for T2 and 64,46±8,05 for T3) (P=0,0036). New research involving the use of hormones and the number of doses of semen need to be repeated.

Este estudo avaliou os efeitos da administração de diferentes doses de eCG em dois momentos distintos no protocolo de sincronização da ovulação para inovulação em tempo fixo. No dia 0, as receptoras foram tratadas com dispositivo intravaginal contendo progesterona (DIP) e 2,0 mg de Benzoato de Estradiol (BE) associados a 50 mg de progesterona (P4) IM. A partir desse momento, os animais foram divididos homogeneamente para receberem 0,15 mg de d-cloprostenol (PGF2&#945;) e 400, 500 ou 600 UI de eCG no dia 5 (G-400d5, n=101; G-500d5, n=98; G-600d5, n=100, respectivamente) ou no dia 8 (G-400d8, n=100; G-500d8, n=99; G-600d8, n=96, respectivamente; fatorial 3x2). O DIP foi retirado no dia 8 e foi administrado 1 mg de BE no dia 9. No dia 17 os animais foram submetidos a ultra-sonografia ovariana e os que apresentaram mais que um corpo lúteo (CL) ou CL único maior que 18 mm de diâmetro receberam um embrião produzido in vitro. Em um grupo de animais, colheu-se amostras de sangue no dia 17 para determinação da concentração plamática de P4 (CPP4). Os animais tratados com eCG no dia 5 apresentaram maior taxa de aproveitamento [87,0 (260/299) vs. 81,7% (241/295), P<0,05], tendência de maior taxa de concepção [51,8 (132/255) vs. 45,0% (108/295), P=0,07], maior taxa de prenhez [44,1 (132/299) vs. 36,6% (108/295), P<0,05], maior número de CL (1,74 ± 0,09 vs. 1,13 ± 0,03, P<0,05) e maior proporção de receptoras com CL único de maior tamanho [CL 22: 65,7 (111/169) vs. 43,1% (94/218), P<0,05] que os tratados no dia 8. Não se observou efeito de dose sobre a taxa de aproveitamento [400: 82,1 (165/201) vs. 500: 83,8 (165/197) vs. 600: 87,2% (171/196), P<0,05], de concepção [400: 51,8 (85/164) vs. 500: 44,1 (71/161) vs. 600: 49,4% (84/170), P<0,05], de prenhez [400: 42,3 (85/201) vs. 500: 36,0 (71/197) vs. 600: 42,9% (84/196), P<0,05] e sobre a quantidade de receptoras com CL único de maior tamanho [400: 46,8 (65/139) vs. 500: 54,9 (73/133) vs. 600: 57,4 (66/115), P<0,05]. Os animais tratados com 600 UI de eCG apresentaram maior número de CL que os que receberam 400 ou 500 UI (400: 1,17 ± 0,03 vs. 500: 1,33 ± 0,06 vs. 600: 1,82 ± 0,12, P<0,05). No grupo que se determinou a CPP4 verificou-se que os animais que receberam eCG no dia 5 apresentaram maiores CPP4 que os do dia 8 (4,68 ± 0,43 vs. 2,73 ± 0,17 ng/ml, P<0,05). As novilhas tratadas com 600 UI de eCG apresentaram maiores CPP que as tratados com 400 ou 500 UI (400: 2,96 ± 0,22 vs. 500: 3,45 ± 0,38 vs. 600: 4,69 ± 0,55, P<0,05). Receptoras com mais de 1 CL apresentaram tendência de menores perdas gestacionais entre 30 e 60 dias de gestação que as com CL único [10,2 (4/49) vs. 17,5% (33/189), P=0,0547]. Os resultados são indicativos de maior eficiência do protocolo de sincronização da ovulação para transferência de embriões em tempo fixo com o uso de eCG no dia 5. A dose de eCG não influenciou na eficiência do tratamento / The aim of this study was to compare the effects of different doses of eCG administrated at two moments in a fixed-time embryo transfer protocol. On day 0, the heifers received a progesterone releasing vaginal insert (PRVI) and an injection of 2.0 mg Estradiol Benzoate (EB) associated with 50 mg progesterone (P4) i.m. The animals were randomly assigned to six treatment groups in a tree by two factorial design to receive 0.15 mg d-cloprostenol (PGF2&#945;) i.m. and 400, 500 or 600 IU eCG on day 5 (G-400d5, n=101; G-500d5, n=98; G-600d5, n=100, respectively) or on day 8 (G-400d8, n=100; G-500d8, n=99; G-600d8, n=96, respectively). On day 8, the PRVI was removed and an injection of 1 mg EB was administered on day 9. On Day 17, all heifers were examined by ultrasonography to determine the number of CL and those with more than one CL or a single CL with a diameter ?18 mm received an in vitro produced embryo. A subset of heifers were bled on day 17 for plasma P4 determination. The animals treated with eCG on day 5 presented higher proportion of heifers selected/treated [87.0 (260/299) vs. 81.7% (241/295), P<0.05], tendency to higher proportion of heifers pregnant/transferred [51.8 (132/255) vs. 45.0% (108/295), P<0.1], higher proportion of heifers pregnant/treated [44.1 (132/299) vs. 36.6% (108/295), P<0.05], higher CL number (1.74 ± 0.09 vs. 1.13 ± 0.03, P<0.05) and higher proportion of recipients with larger single CL [CL 22: 65.7 (111/169) vs. 43.1% (94/218), P<0.05] than those treated with eCG on day 8. Dose effects were not observed in the proportion of heifers selected/treated [400: 82.1 (165/201) vs. 500: 83.8 (165/197) vs. 600: 87.2% (171/196), P<0.05], pregnant/transferred [400: 51.8 (85/164) vs. 500: 44.1 (71/161) vs. 600: 49.4% (84/170), P<0.05], pregnant/treated [400: 42.3 (85/201) vs. 500: 36.0 (71/197) vs. 600: 42.9% (84/196), P<0.05] and proportion of recipients with larger single CL [400: 46.8 (65/139) vs. 500: 54.9 (73/133) vs. 600: 57.4 (66/115), P<0.05]. The animals that received 600 IU eCG presented higher CL number than those received 400 and 500 IU (400: 1.17 ± 0.03 vs. 500: 1.33 ± 0.06 vs. 600: 1.82 ± 0.12, P<0.05). In a subset of heifers that was performed a plasma P4 determination, the group that received eCG on day 5 presented higher plasmatic P4 concentration than those received eCG on day 8 (4.68 ± 0.43 vs. 2.73 ± 0.17 ng/ml, P<0.05). The use of 600 IU eCG presented higher plasmatic P4 concentration than 500 and 600 IU (400: 2.96 ± 0.22 vs. 500: 3.45 ± 0.38 vs. 600: 4.69 ± 0.55, P<0.05). Recipients with more than 1 CL tended to present lower pregnancy losses between 30 and 60 days than those with a single CL [10.2 (4/49) vs. 17.5% (33/189), P=0.0547]. The results suggest higher efficiency in the synchronization of ovulation protocol for fixed-time embryo transfer with eCG administration on day 5. The dose of eCG did not affect the efficiency of treatment

A pesquisa desenvolvida no Laboratório de Pesquisa em Suínos, da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo, Campus de Pirassununga, estudou os efeitos de diferentes doses de LH suíno exógeno na indução e sincronização da puberdade em marrãs. Sessenta e sete fêmeas Camborough - 22 Agroceres PIC® com 140 dias de idade e 86 kg de peso vivo foram submetidas aos seguintes tratamentos: controle T1 (n = 21) - emprego de 600 UI de eCG (gonadotrofina coriônica eqüina) (Novormon&reg) e 72 horas depois 5,0 mg de LH (hormônio luteinizante) (Lutropin® - V); tratamento 2 T2(n = 23) - 600 UI de eCG (Novormon®) e, 72 horas depois, 2,5 mg de LH (Lutropin® - V) e tratamento 3 T3(n=23) - 600 UI de eCG (Novormon®) e, 72 horas depois, 1,25 mg de LH (Lutropin® - V). O estímulo com macho adulto era feito duas vezes ao dia, sendo a ovulação detectada pela ultra-sonografia transcutânea e a taxa de ovulação, pela contagem do número de corpos lúteos (CL) ao abate. O percentual de estro foi semelhante entre T1 (42,85%), T2 (60,87%) e T3 (52,18%), não havendo diferença estatística significativa (P=0,418). O percentual de fêmeas com degenerações císticas foi de 33,33% (T1); 39,13%(T2) e 39,13%(T3), não havendo diferença significativa entre os tratamentos (P=0,9057). O melhor intervalo tratamento - ovulação (LH - OV) ocorreu no grupo de fêmeas submetidas ao T2 (38,26 ± 2,84) demonstrado pela menor dispersão dos desvios comparando com T1 (37,17 ± 4,07) e T3 (36,25± 5,69), sendo o valor do desvio padrão diferente estatisticamente do de T3, porém igual ao valor de T1 sendo ainda o valor de T1 igual ao de T3(P<0,05). O intervalo entre a aplicação de eCG e estro do T1(85,33 ± 12,64 horas), T2 (84,40 ±17,50 horas) e T3 (89,14 ± 14,66 horas) foram semelhantes não havendo diferença estatística significativa (P= 0,6954). A duração do estro foi semelhante entre os três tratamentos (P = 0,2653), sendo de 41,44 ± 16,30 horas (T1); 48,57 ± 16,29 horas (T2); 39,33 ± 11,42 horas (T3). O número de Corpos Lúteos em T1 foi de 9,61 ± 5,43 (1-25); em T2 de 9,86 ±3,32 (1-16); em T3 de 8,13 ± 5,52 (0-20), não constatando diferença significativa (P=0,4259). Os menores desvios observados no tratamento T2 sugerem que a combinação de 600 UI de eCG seguida por 2,5 mg de LH após 72 horas, foi a mais efetiva na indução e sincronização do estro e ovulação em fêmeas suínas pré-púberes, considerando a metodologia experimental empregada. Na segunda parte do experimento, foram realizadas inseminações artificiais em tempo fixo em dois esquemas (E) diferentes: O (E1) recebeu uma única dose 36 h após a aplicação de LH e, o (E2) recebeu a primeira dose 24 h e a segunda dose 36 h após a aplicação de LH. As marrãs foram abatidas com 5 dias de gestação e os embriões foram colhidos. Não verificou-se diferença estatística entre os valores obtidos na taxa de recuperação (36,81±5,21 para E1 e 36,91±4,62 para E2), taxa de viabilidade embrionária (TVE) (59,28±6,91 para E1 e 62,25±6,26 para E2), taxa de fecundação (TF) (72,60±7,06 para E1 e 79,33±6,26 para E2) e número de estruturas totais (3,41±0,57 para E1 e 3,77±0,50 para E2) entre E1 e E2. Houve interação significativa entre tratamento e número de doses de sêmen para as variáveis TVE (T1=60,51± 8,18, T2=68,64±7,94 e T3=53,14±7,8) e TF (73,50±8,36 para T1, 89,93±8,11 para T2 e 64,46±8,05 para T3) (P=0,0036). Novos estudos envolvendo aplicação dos hormônios e n° de doses de sêmen, necessitam serem repetidos. / The research carried out at the Swine Research Laboratory, of FMVZ - USP, Campus of Pirassununga, studied the effects of the use of different hormonal doses on the induction and synchronization of puberty in gilts. Sixty-seven Camborough 22 Agroceres PIC® females with 140 days of age and 86kg of body weight were submitted to the following treatments: control T1 (n=21) - use of 600 IU of eCG (equine chorionic gonadotrophin) (Novormon®) and 72 hours later 5,0 mg of LH (Luteinizing hormone) (Lutropin® - V); treatment 2 T2 (n = 23) - 600 UI of eCG (Novormon®) and 72 hours later 2,5mg of LH (Lutropin® - V) and treatment 3 T3 (n = 23) - 600 UI of eCG (Novormon®) and 72 hours later 1,25mg of LH (Lutropin® - V). Adult boar stimulation was implemented twice a day, and ovulation was detected through transcutaneous ultrasonography and ovulation rate by corpora lutea (CL) counting at slaughter. The percentage of estrus was similar in T1 (42,85%), T2 (60,87%) and T3 (52,18%), and there was no significant statistic difference (P=0,418). The percentage of females with cystic degeneration was 33,33% (T1); 39,13%(T2) and 39,13%(T3), being no significant difference between the treatments (P=0,9057). The best interval between treatment and estrus (LH - OV) occurred in the group of females submitted to T2 (38,26 ± 2,84) demonstrated by lesser dispersion of the deviations comparing to T1 (37,17 ± 4,07) and T3 (36,25± 5,69); standard deviation was statistically different from T3, but similar to T1, and T1 was also similar to T3 (P<0,05). The interval between the administration of eCG and estrus in T1 (85,33 ± 12,64 hours), T2 (84,40 ±17,50 hours) and T3 (89,14 ± 14,66 hours) were similar, and there was no significant statistic difference (P= 0,6954). The duration of estrous was similar among the three treatments (P = 0,2653), being 41,44 ± 16,30 hours (T1); 48,57 ± 16,29 hours (T2); 39,33 ± 11,42 hours (T3). The number Corpus Luteum in T1 was 9,61 ± 5,43 (1-25); in T2 was 9,86 ±3,32 (1-16); in T3 was 8,13 ± 5,52 (0-20), and there was no significant difference (P=0,4259). The minor deviations observed in treatment T2 suggest that the association of 600 UI of eCG followed by 2,5 mg of LH after 72 hours, was more effective in the induction and synchronization of estrous and ovulation in pre-puberty female swine, considering the experimental methodology used. In the second part of the experiment, artificial insemination was performed at determined timing following two different programs (E). E1 received a single dose 36 hours after administration of LH and E2 received the first dose after 24 hours and the second dose 36 hours after the administration of LH. The gilts were slaughtered with 5 days of pregnancy and the embryos were collected. No statistic difference was observed among the values obtained for recovery rate (36,81±5,21 for E1 and 36,91±4,62 for E2), embryonary viability rate (TVE) (59,28±6,91 for E1 and 62,25±6,26 for E2), fecundation rate (TF) (72,60±7,06 for E1 and 79,33±6,26 for E2) and number of total structures (3,41±0,57 for E1 and 3,77±0,50 for E2) among E1 and E2. There was significant interaction between treatment and the number of doses of semen for the values TVE (T1=60,51± 8,18, T2=68,64±7,94 and T3=53,14±7,8) and TF (73,50±8,36 for T1, 89,93±8,11 for T2 and 64,46±8,05 for T3) (P=0,0036). New research involving the use of hormones and the number of doses of semen need to be repeated.

A aplicação de drogas durante o diestro para melhorar a taxa de prenhez na égua inseminada e na receptora de embrião tem sido o foco de alguns grupos de pesquisa. Estudos com hCG encontraram resultados promissores nas taxas de prenhez e características uterinas de receptoras de embrião no dia da transferência. Com o objetivo de avaliar o efeito da aplicação da hCG em diferentes momentos do ciclo estral sobre as características do trato reprodutivo, vascularização e concentração sérica de progesterona, os animais foram submetidos à aplicação da hCG para induzir ovulação, no dia da ovulação e no 5o dia pós ovulação, além do grupo controle. O presente trabalho foi dividido em estudo preliminar com 4 animais em cada grupo e um estudo principal, com 12 animais por grupo sendo que todos os animais foram submetidos a todos os tratamentos. As características examinadas ao longo dos 15 dias pós ovulação foram tônus, morfoecogenicidade e vascularização do útero; tônus da cérvix; o diâmetro e área do corpo lúteo e do pedículo ovariano e seu RI; RI e vascularização mesometrial. Além disso, amostras de sangue para mensuração sérica de progesterona foram coletadas. Não foi encontrado efeito do tratamento nas características avaliadas com hCG em nenhum dos grupos. As características somente apresentaram variação ao longo do tempo, conforme descrito na literatura. Novos estudos avaliando o efeito da hCG em éguas devem ser realizados para averiguar outras variáveis e possíveis efeitos. / The use of drugs during diestrus in order to improve conception rates in inseminated and recipient mares has been the focus of several research groups. Studies using hCG found promising results regarding pregnancy rates and recipient uterine characteristics on the Day of the transfer. The objective of the study was to evaluate the effect of hCG administration in different moments of the oestrous cycle on reproductive tract characteristics, vascularization and serum progesterone concentration. Therefore, groups consisted of control, hCG to induce ovulation; hCG on day 0 and hCG on day 5 postovulation. The current study was performed as a preliminar study with 4 animals per group, one cycle each animal and a main study with 12 animals per group, each animal receiving all the treatments during consecutive cycles. The evaluations were performed daily from day 0 until day 15 postovulation. Characteristics examined were uterine tone, morphoecogenicity and vascularization; cervical tone; area, diamaterand vascularization of the corpus luteum, ovarian pedicle vascularization and RI; mesometrial vascularization and RI. Besides, blood samples were collected for serum progesterone concentration. No diferences were detected comparing treated and control groups. The characteristics only varied through the days, as described in the literature. Therefore, it can be concluded that hCG administered to induce ovulation, on the day of ovulation and on day 5 postovulation did not alter the characteristics evaluated in the current study.

A aplicação de drogas durante o diestro para melhorar a taxa de prenhez na égua inseminada e na receptora de embrião tem sido o foco de alguns grupos de pesquisa. Estudos com hCG encontraram resultados promissores nas taxas de prenhez e características uterinas de receptoras de embrião no dia da transferência. Com o objetivo de avaliar o efeito da aplicação da hCG em diferentes momentos do ciclo estral sobre as características do trato reprodutivo, vascularização e concentração sérica de progesterona, os animais foram submetidos à aplicação da hCG para induzir ovulação, no dia da ovulação e no 5o dia pós ovulação, além do grupo controle. O presente trabalho foi dividido em estudo preliminar com 4 animais em cada grupo e um estudo principal, com 12 animais por grupo sendo que todos os animais foram submetidos a todos os tratamentos. As características examinadas ao longo dos 15 dias pós ovulação foram tônus, morfoecogenicidade e vascularização do útero; tônus da cérvix; o diâmetro e área do corpo lúteo e do pedículo ovariano e seu RI; RI e vascularização mesometrial. Além disso, amostras de sangue para mensuração sérica de progesterona foram coletadas. Não foi encontrado efeito do tratamento nas características avaliadas com hCG em nenhum dos grupos. As características somente apresentaram variação ao longo do tempo, conforme descrito na literatura. Novos estudos avaliando o efeito da hCG em éguas devem ser realizados para averiguar outras variáveis e possíveis efeitos. / The use of drugs during diestrus in order to improve conception rates in inseminated and recipient mares has been the focus of several research groups. Studies using hCG found promising results regarding pregnancy rates and recipient uterine characteristics on the Day of the transfer. The objective of the study was to evaluate the effect of hCG administration in different moments of the oestrous cycle on reproductive tract characteristics, vascularization and serum progesterone concentration. Therefore, groups consisted of control, hCG to induce ovulation; hCG on day 0 and hCG on day 5 postovulation. The current study was performed as a preliminar study with 4 animals per group, one cycle each animal and a main study with 12 animals per group, each animal receiving all the treatments during consecutive cycles. The evaluations were performed daily from day 0 until day 15 postovulation. Characteristics examined were uterine tone, morphoecogenicity and vascularization; cervical tone; area, diamaterand vascularization of the corpus luteum, ovarian pedicle vascularization and RI; mesometrial vascularization and RI. Besides, blood samples were collected for serum progesterone concentration. No diferences were detected comparing treated and control groups. The characteristics only varied through the days, as described in the literature. Therefore, it can be concluded that hCG administered to induce ovulation, on the day of ovulation and on day 5 postovulation did not alter the characteristics evaluated in the current study.

Several cancers are associated with abnormal serum concentrations of tumor markers such as prostate specific antigen (PSA) in prostate tumor diseases, alfa-fetoprotein (AFP) or human chorionic gonadotrophin (hCG) in germ cell tumors or persistent gestational trophoblastic diseases (GTD). Cancer treatment should induce decline of serum tumor marker concentrations. The predictive values of many kinetic parameters supposed to characterize tumor marker declines such as nadir, time-point cutoff, half-life, time to normalization etc..., have been reported in previous studies. However very few of them have been used in routine due to the lack of outcome reproducibility. Population pharmacokinetic approach-based modeling is already used in pharmacokinetic studies. It might be helpful to characterize tumor marker decline equations dynamically and overcome limitations of previous studies. The feasibility and the relevance of this approach were assessed in 4 studies involving: PSA titers in patients with prostate adenoma or cancer treated with surgery; hCG-AFP in non-seminomatous germ cell tumor patients treated with BEP regimen (Bleomycin-Etoposide-Cisplatin) and hCG in GTD patients treated with methotrexate. Tumor marker decline modeling was feasible in all studies provided the methodology was adjusted to marker specificities. Apparent clearance of hCG and PSA might enable identification of patients with unfavorable decline profiles and thereby with high risk of relapse. Confirmatory studies with independent cohorts of patients are warranted

Plusieurs cancers sont associés à des concentrations sériques anormales de marqueurs tumoraux, tels que le prostate specific antigen (PSA) dans le cancer de prostate, l’alfafoetoproteine (AFP) ou l’human chorionic gonadotrophin (hCG) dans les tumeurs germinales ou les maladies trophoblastiques gestationnelles (MTG). Le traitement du cancer doit s’accompagner d’une chute de leurs concentrations. Les valeurs prédictives de nombreux paramètres cinétiques censés caractériser la décroissance des marqueurs ont été publiées dans la littérature (nadir, valeur seuil, demi-vie, temps à normalisation etc…) Cependant très peu de ces paramètres sont utilisés en pratique par manque de reproductibilité. La modélisation en approche de cinétique de population, déjà utilisée dans les études pharmacocinétiques, permettrait de caractériser de façon dynamique la décroissance des marqueurs tumoraux sériques et de compenser les limites des autres méthodes. Nous avons étudié la faisabilité et l’intérêt de cette approche dans 4 études portant sur le PSA après chirurgie d’adénome ou de cancer de la prostate, l’hCG-AFP dans les tumeurs germinales non-séminomateuses traitées par polychimiothérapie de type Bléomycine-Etoposide- Cisplatine (BEP) et l’hCG dans les MTG traitées par méthotrexate. La modélisation de la décroissance des marqueurs tumoraux a été possible dans toutes les études en adaptant la méthodologie aux spécificités de chaque marqueur. Il apparaît que les clairances apparentes du PSA et de l’hCG permettraient d’identifier les patients ayant des profils cinétiques défavorables et donc à haut risque de rechute. Des études de validation sur des cohortes indépendantes sont nécessaires / Several cancers are associated with abnormal serum concentrations of tumor markers such as prostate specific antigen (PSA) in prostate tumor diseases, alfa-fetoprotein (AFP) or human chorionic gonadotrophin (hCG) in germ cell tumors or persistent gestational trophoblastic diseases (GTD). Cancer treatment should induce decline of serum tumor marker concentrations. The predictive values of many kinetic parameters supposed to characterize tumor marker declines such as nadir, time-point cutoff, half-life, time to normalization etc…, have been reported in previous studies. However very few of them have been used in routine due to the lack of outcome reproducibility. Population pharmacokinetic approach-based modeling is already used in pharmacokinetic studies. It might be helpful to characterize tumor marker decline equations dynamically and overcome limitations of previous studies. The feasibility and the relevance of this approach were assessed in 4 studies involving: PSA titers in patients with prostate adenoma or cancer treated with surgery; hCG-AFP in non-seminomatous germ cell tumor patients treated with BEP regimen (Bleomycin-Etoposide-Cisplatin) and hCG in GTD patients treated with methotrexate. Tumor marker decline modeling was feasible in all studies provided the methodology was adjusted to marker specificities. Apparent clearance of hCG and PSA might enable identification of patients with unfavorable decline profiles and thereby with high risk of relapse. Confirmatory studies with independent cohorts of patients are warranted